Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
BMC Neurol ; 21(1): 185, 2021 May 03.
Article in English | MEDLINE | ID: mdl-33941099

ABSTRACT

BACKGROUND: Morvan syndrome (MoS) is a rare autoimmune syndrome associated with antibodies against two kinds of potassium channel proteins, contactin associated protein-like 2 (CASPR2) and leucine-rich glioma inactivated protein 1 (LGI1). MoS patients with only LGI1-antibody seropositivity have rarely been reported. Here, we describe a 64-year-old male MoS patient with only LGI1-antibody seropositivity. CASE PRESENTATION: A 64-year-old male patient was referred to our hospital due to limb pain, widespread myokymia, insomnia, constipation, and hyperhidrosis for 1 month. The patient was diagnosed with MoS based on the clinical symptoms and positive LGI1-antibody in serum. He was treated with intravenous immunoglobulin (IVIG), intravenous methylprednisolone followed by oral prednisone, and other drugs for symptomatic relief. Several days later, myokymia and insomnia symptoms improved. After 60 days of follow-up, all the drugs had been stopped for 2 weeks, and the patient achieved complete remission without any medical side effects. CONCLUSION: We report the clinical characteristics of a Chinese MoS patient with only LGI1-antibody seropositivity, and further support the view that non-neoplasm MoS patients respond well to immunotherapy.


Subject(s)
Autoimmune Diseases/immunology , Intracellular Signaling Peptides and Proteins/immunology , Adult , Autoantibodies/blood , Autoantigens/immunology , Autoimmune Diseases/drug therapy , Humans , Immunoglobulins, Intravenous/therapeutic use , Male , Syndrome
2.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 27(7): 640-2, 2007 Jul.
Article in Chinese | MEDLINE | ID: mdl-17717928

ABSTRACT

OBJECTIVE: To evaluate the efficacy of Wuling Capsule (WLC) in treating patients with poststroke depression. METHODS: One hundred and eight patients with poststroke depression were randomly assigned to three groups, 36 in each. All were treated with routine medicine, but to the WLC group and the FLX group, additional WLC and fluoxetine was given respectively, while to the combined group, both of the two were given. Patients' neurological and cognitive function were estimated by HAMI) scale, MMSE scale, SSS scale and Barthel index (BI) before treatment and at 4 weeks and 12 weeks after treatment. RESULTS: HAMD score and SSS score significantly decreased (P < 0.01) while MMSE score and BI score significantly increased (P <0.05) in all the three groups, but the improvement in decrease of HAMD score and in increase of BI score in the combined group was more significant than those in the other two groups respectively (P<0.05). CONCLUSIONS: WLC is effective in treating patients with poststroke depression and shows synergism with fluoxetine.


Subject(s)
Depression/drug therapy , Drugs, Chinese Herbal/therapeutic use , Fluoxetine/therapeutic use , Stroke/complications , Aged , Antidepressive Agents, Second-Generation/therapeutic use , Capsules , Depression/etiology , Depression/psychology , Drug Synergism , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Phytotherapy , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL